Flexion Therapeutics Announces Kerry Wentworth, Chief Regulatory Officer, Appointed to Massachusetts Biotechnology Council Bo...
April 01 2019 - 9:00AM
Flexion Therapeutics today announced that Kerry Wentworth, Chief
Regulatory Officer, has been appointed to the Massachusetts
Biotechnology Council (MassBio) Board of Directors.
“It is a pleasure to welcome Kerry to our Board of Directors,”
said Robert K. Coughlin, President and CEO of MassBio. “Kerry
is an experienced and highly-regarded leader in the life sciences
industry, and we are confident her insights and business acumen
will be invaluable to our member organizations and the individuals
we serve.”
MassBio is a not-for-profit organization representing more than
1,100 life sciences companies, academic institutions, disease
foundations, and other organizations involved in healthcare. The
MassBio Board of Directors comprises a select group of leaders
committed to guiding the organization in its mission to
grow Massachusetts' life sciences industry, add value to
the healthcare system, and improve patient lives.
“I am honored to join the MassBio Board, and I look forward to
collaborating with my esteemed colleagues as we work to advance
healthcare policy, promote education and, most importantly, improve
the lives of patients,” said Ms. Wentworth.
Ms. Wentworth brings to the MassBio Board of Directors deep
expertise in both domestic and international Regulatory Affairs
that spans early and late development across multiple therapeutic
areas. Prior to joining Flexion, Ms. Wentworth served as Vice
President, Clinical, Regulatory and Quality at Agenus, Inc., where
she was responsible for leading all global regulatory and clinical
development efforts for nearly 10 years. Previously, Ms. Wentworth
led the Regulatory and Quality function for Genelabs Technologies,
Inc., where she was responsible for advancing their lead program
through Phase 3 development and into the registration phase with
FDA and EMA. Ms. Wentworth also held positions of increasing
responsibility within Regulatory Affairs at Genzyme.
For more information, please visit the MassBio website
at www.massbio.org.
About Flexion Therapeutics Flexion
Therapeutics (Nasdaq:FLXN) is a biopharmaceutical company
focused on the development and commercialization of novel, local
therapies for the treatment of patients with musculoskeletal
conditions, beginning with osteoarthritis, a type of degenerative
arthritis. The company's core values are focus, ingenuity,
tenacity, transparency and fun. For the past two years, Flexion has
been named one of the Best Places to Work by the Boston
Business Journal, and a Top Place to Work
in Massachusetts by The Boston Globe.
About MassBioMassBio is a not-for-profit
organization founded in 1985 that represents and provides services
and support for the world’s leading life sciences supercluster.
MassBio is committed to advancing Massachusetts' leadership in the
life sciences to grow the industry, add value to the healthcare
system and improve patient lives. Representing 1,100+ biotechnology
companies, academic institutions, disease foundations and other
organizations involved in life sciences and healthcare, MassBio
leverages its unparalleled network of innovative companies and
industry thought leaders to advance policy and promote education,
while providing member programs, events, industry information, and
services. For more information, visit www.massbio.org.
Contacts:
Scott YoungVice President, Corporate Communications &
Investor RelationsFlexion Therapeutics, Inc.T:
781-305-7194syoung@flexiontherapeutics.com
Julie DownsSenior Manager, Corporate Communications &
Investor RelationsFlexion Therapeutics, Inc.T:
781-305-7137jdowns@flexiontherapeutics.com
A photo accompanying this announcement is available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/f611e177-b1a9-4801-94dd-c53da759436d
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Flexion Therapeutics (NASDAQ:FLXN)
Historical Stock Chart
From Apr 2023 to Apr 2024